Compliance Testing for Medicines According to ICH Guidelines: Stability, Bioavailability, and Analytical Validation
The approval and market introduction of a pharmaceutical product is not only possible through efficacy and safety data, but also through the scientific proof of its quality and consistency. In this context, the ICH guidelines (International Council for Harmonisation) establish internationally recognized standards for drug development and manufacturing. These guidelines, which apply in more than 40 countries, including Turkey, define how critical compliance tests such as stability tests, bioavailability/bioequivalence studies, and analytical validation are to be conducted.
In this blog post, we will discuss the basic categories of drug compliance testing according to the ICH guidelines, explain which guidelines cover which tests, and introduce Nano-Test's GLP-compliant services in this area.
What are ICH guidelines and why are they important?
The ICH is an international organization founded by representatives of the pharmaceutical industry and regulatory authorities in Europe, Japan, and the USA. Its goal is to harmonize the technical requirements in the processes of drug development and approval, thus avoiding duplicate tests and ensuring that new drugs reach patients faster.
The ICH guidelines can be divided into four main categories:
- Quality Guidelines (Q): They cover topics such as stability, analytical validation, impurities, pharmacopoeia compliance, and Good Manufacturing Practice (GMP).
- Safety Guidelines (S): They cover toxicological and pharmacological studies.
- Efficacy Guidelines (E): They cover clinical studies as well as evaluations of bioavailability and bioequivalence.
- Multidisciplinary Guidelines (M): They cover topics such as MedDRA and electronic standards.
1. Stability Tests (I-Q1 Series)
Stability tests assess how an active ingredient or drug maintains its quality characteristics over time and under the influence of environmental factors (temperature, humidity, light). These tests are mandatory to determine the shelf life of the product and the appropriate storage conditions.
I-Q1 guidelines and their scope
- ICH Q1A(R2): Stability testing for new drug substances and medicinal products. Defines long-term, intermediate, and accelerated testing conditions.
- ICH Q1B: Photostability testing (light stability).
- ICH Q1C: Stability testing for new dosage forms.
- ICH Q1D: Bracketing and matrixing designs in stability testing.
- ICH Q1E: Evaluation of stability data and prediction of shelf life.
The parameters monitored in the context of stability tests include quality criteria such as appearance, color, pH value, dissolution rate, water content, contaminant profile and salary determination. These parameters are analyzed at fixed time intervals (0, 3, 6, 9, 12, 18, 24, 36 months).
2. Bioavailability and Bioequivalence Tests (I-E Series)
Bioavailability (BA) refers to the proportion and rate at which an active ingredient enters the systemic circulation after ingestion. The bioequivalence (BE), on the other hand, assesses whether the bioavailability of two different products (e.g. a generic and a reference product) is statistically similar.
Relevant I Guides
- ICH E6(R2): Guideline for Good Clinical Practice (GCP).
- ICH M13A: Bioequivalence assessment for immediate-release solid oral dosage forms.
- ICH M13B: Bioequivalence for products with additional drug strength and modified release.
Bioequivalence studies are usually clinical trials conducted on healthy subjects and comparing plasma concentration-time curves. Basic parameters: Cmax (maximum concentration), AUC (area under the curve) and Tmax (time to reach the maximum concentration).
3. Analyzes and Quantitative Analyzes (Ich Q2 and Q14)
Analytical methods form the basis for all tests that are used in the quality control of a drug. The ICH Q2(R2) guidelines and the newly published IQ14 provide a current framework for the validation and development of analytical methods.
I Q2(R2) - Analytical Validation
This guide defines the parameters to be taken into account when validating analytical methods:
- Accuracy: The closeness of the measured value to the true value.
- Precision: Repeatability and internal precision.
- Specificity: The ability of the method to correctly measure the analyte despite the presence of impurities and matrix components.
- Limit of Detection (LOD) and Limit of Quantification (LOQ): The lowest concentration that can be detected with the method.
- Linearity and Range: The concentration range in which the method responds linearly.
- Robustness: The resistance of the method to small experimental variations.
Q14 - Development of analytical methods
The IQ14, which came into force in 2023, introduced the “Quality by Design (QBD)” approach to the process of developing analytical methods. This guide recommends pre-determining the critical parameters (ATP) that affect the method's performance and optimize the method according to these targets.
Comparison of ICH Conformity Tests and related guidelines
The following table summarizes the ICH guidelines to carry out drug compliance tests:
| Test category | Related ego guide | Evaluated parameters | Purpose of Use |
|---|---|---|---|
| Stress tests | I Q1A(R2), Q1B, Q1C, Q1D, Q1E | Shelf life, storage conditions, mining profile | Proof of product quality over time |
| Bioavailability / Bioequivalence | I E6(R2), M13A, M13B | Cmax, AUC, Tmax, statistical equivalence | Detection of the equivalence of generics to the reference product |
| Analytical Validation | I Q2(R2), Q14 | Accuracy, Accuracy, Specificity, Lod, Loq, Linearity | Proof of reliability of analytical methods |
| Salary determination (assay) | I Q2(R2), Q6A | API content, potency, salary homogeneity | Checking the active substance content of the product |
| Contamination profile | I Q2A, Q3B, Q3C, Q3D | Organic impurities, solvent residues, heavy metals | Check for substances that endanger the safety of the product |
I-compliant conformity testing services with nano-test
In the context of drug development and the approval process, it is crucial that the tests are conducted according to the ICH guidelines and the results are documented in an internationally recognized format. Nano-Test with its GLP and ISO/IEC 17025 accredited laboratories is your reliable partner in this process.
Nano-Test – Performance Description
Nano-Test offers compliance testing according to ICH guidelines for the pharmaceutical industry. Our service portfolio is divided into three main categories:
- Stability Testing (ICH Q1): Long-term, intermediate, and accelerated stability studies; photostability (Q1B); bracketing and matrixing designs (Q1D); prediction of shelf life (Q1E). Our climate chambers fully comply with ICH conditions (25 °C/60 % r. H., 30 °C/65 % r. H., 40 °C/75 % r. H.).
- Bioavailability and Bioequivalence (ICH M13A): Validation of bioanalytical methods, analysis of plasma samples, calculation of pharmacokinetic parameters (Cmax, AUC, Tmax) and statistical evaluation of bioequivalence.
- Analytical Validation and Quantification (ICH Q2(R2)/Q14): Method development, validation, and routine analyses using HPLC, GC, LC-MS/MS, and ICP-MS. All parameters regarding accuracy, precision, specificity, LOD, LOQ, linearity, and robustness are evaluated.
All our work is carried out according to the ICH guidelines and the monographs of the pharmacopoeias (USP, EP, JP). Data integrity (ALCOA+ principles) is ensured and defensible during inspections by regulatory authorities GLP conformity reports are created.
The advantages of nano-test in ICH conformity tests:
- One-stop solution: All services in the areas of stability, bioanalytical, and analytical validation under one roof.
- Tracking current legal requirements: Immediate adaptation to newly published guidelines such as ICH Q14.
- State-of-the-art technological infrastructure: LC-MS/MS, GC-MS/MS, ICP-MS, HPLC-DAD, and climate chambers.
- Expert team: A team of experienced chemists and pharmacists in the fields of pharmaceutical analysis, bioanalysis, and validation.
- Fast reporting: Delivery of results within 5–10 working days for standard analyses.
The safety, efficacy, and quality of medicines are ensured through comprehensive tests conducted according to the ICH guidelines. Stability tests determine the shelf life of the product, while bioavailability/bioequivalence studies prove the equivalence of generics with the reference product. Analytical validation forms the basis for the reliability of all these tests.
Nano-Test fully meets the requirements of the drug manufacturers in the field of conformity testing with its fully ICH-compliant infrastructure, its expert team and its GLP-certified processes. Collaborate with Nano-Test to speed up your application for admission and meet the requirements of the regulatory authorities.